M. Ravic

1.2k total citations
36 papers, 973 citations indexed

About

M. Ravic is a scholar working on Oncology, Pharmacology and Surgery. According to data from OpenAlex, M. Ravic has authored 36 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pharmacology and 7 papers in Surgery. Recurrent topics in M. Ravic's work include Pharmacogenetics and Drug Metabolism (8 papers), Drug Transport and Resistance Mechanisms (6 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). M. Ravic is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Drug Transport and Resistance Mechanisms (6 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). M. Ravic collaborates with scholars based in United Kingdom, Netherlands and Germany. M. Ravic's co-authors include Philippe Jornod, D. Pantoflickova, Gian Dorta, A. L. Blum, P. Fumoleau, Jan H.M. Schellens, Achim Rothe, J. Wanders, Dennis A. Eichenauer and Georg Kuhnert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

M. Ravic

35 papers receiving 930 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Ravic United Kingdom	14	398	299	222	198	151	36	973
Catherine Dutreix Switzerland	20	347 0.9×	687 2.3×	59 0.3×	243 1.2×	73 0.5×	28	1.9k
P. A. Philip United States	21	800 2.0×	601 2.0×	261 1.2×	60 0.3×	93 0.6×	81	1.5k
Katsusuke Satake Japan	19	616 1.5×	295 1.0×	722 3.3×	114 0.6×	73 0.5×	103	1.3k
Stratigoula Sakellariou Greece	19	398 1.0×	480 1.6×	286 1.3×	98 0.5×	65 0.4×	77	1.3k
Yu Sunakawa Japan	25	1.2k 3.0×	465 1.6×	256 1.2×	150 0.8×	45 0.3×	183	1.8k
Marcus A. Wörns Germany	26	229 0.6×	356 1.2×	300 1.4×	187 0.9×	22 0.1×	49	1.8k
Amit Garg United States	18	372 0.9×	325 1.1×	180 0.8×	153 0.8×	37 0.2×	39	1.1k
Xinsen Xu China	20	469 1.2×	427 1.4×	302 1.4×	112 0.6×	60 0.4×	46	1.3k
Angelica Petrillo Italy	19	551 1.4×	233 0.8×	237 1.1×	114 0.6×	73 0.5×	68	1.1k
Jun Hihara Japan	24	466 1.2×	322 1.1×	803 3.6×	167 0.8×	147 1.0×	128	1.7k

Countries citing papers authored by M. Ravic

Since Specialization

Citations

This map shows the geographic impact of M. Ravic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ravic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ravic more than expected).

Fields of papers citing papers by M. Ravic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ravic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ravic. The network helps show where M. Ravic may publish in the future.

Co-authorship network of co-authors of M. Ravic

This figure shows the co-authorship network connecting the top 25 collaborators of M. Ravic. A scholar is included among the top collaborators of M. Ravic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ravic. M. Ravic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arends, Tom J.H., Rianne J.M. Lammers, Antoine G. van der Heijden, et al.. (2014). Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 13(3). 204–209.e2. 15 indexed citations

Rothe, Achim, Stephanie Sasse, Max S. Topp, et al.. (2014). Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab. Blood. 124(21). 1753–1753. 1 indexed citations

Zhukovsky, Eugene A., Achim Rothe, Bastian von Tresckow, et al.. (2013). A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood. 122(21). 5116–5116. 3 indexed citations

Bytzer, Peter, et al.. (2006). Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scandinavian Journal of Gastroenterology. 41(10). 1132–1140. 18 indexed citations

Kesteren, Charlotte van, Anthe S. Zandvliet, Mats O. Karlsson, et al.. (2005). Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investigational New Drugs. 23(3). 225–234. 47 indexed citations

Smyth, J F, Ahmad Awada, Christian Dittrich, et al.. (2004). Phase II study of E7070 in patients with metastatic melanoma. Annals of Oncology. 16(1). 158–161. 46 indexed citations

Ravic, M., Steve Warrington, Malcolm Boyce, Kate M. Dunn, & A. E. Johnston. (2004). Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single‐dose thioridazine in young volunteers. British Journal of Clinical Pharmacology. 58(s1). 34–40. 6 indexed citations

Ravic, M.. (2003). Intracavitary Treatment of Malignant Gliomas: Radioimmunotherapy Targeting Fibronectin. PubMed. 88. 77–82. 6 indexed citations

Pantoflickova, D., Gian Dorta, M. Ravic, Philippe Jornod, & A. L. Blum. (2003). Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Alimentary Pharmacology & Therapeutics. 17(12). 1507–1514. 116 indexed citations

10.

Terret, C., Sylvie Zanetta, Henri Roché, et al.. (2003). Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). European Journal of Cancer. 39(8). 1097–1104. 41 indexed citations

11.

Hawkey, Christopher J., et al.. (2003). Safety and efficacy of 7‐day rabeprazole‐ and omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Alimentary Pharmacology & Therapeutics. 17(8). 1065–1074. 36 indexed citations

12.

Bongard, H.J.G.D. van den, Dick Pluim, Robert C.A.M. van Waardenburg, et al.. (2003). In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anti-Cancer Drugs. 14(6). 405–410. 9 indexed citations

13.

Bongard, H.J.G.D. van den, Dick Pluim, Hilde Rosing, et al.. (2002). An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anti-Cancer Drugs. 13(8). 807–814. 13 indexed citations

14.

Kesteren, Charlotte van, Ron A. A. Mathôt, Éric Raymond, et al.. (2002). Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N‐(3‐chloro‐7‐indolyl)‐1,4‐benzenedisulphonamide). British Journal of Clinical Pharmacology. 54(5). 463–471. 8 indexed citations

15.

Punt, Cornelis J. A., et al.. (2001). Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG). Annals of Oncology. 12(9). 1289–1293. 46 indexed citations

16.

Ravic, M., et al.. (2001). Rebeprazole vs omeprazole in 7-day, triple-therapy H pylori eradication regimens for peptic ulcer. Gastroenterology. 120(5). A581–A581. 2 indexed citations

17.

Fumoleau, P., Hoffmann-La Roche, Christian Dittrich, et al.. (2000). Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. UCL Discovery (University College London). 7 indexed citations

18.

Warrington, SJ, et al.. (1993). Renal and General Tolerability of Repeated Doses of Nimesulide in Normal Subjects. Drugs. 46(Supplement 1). 263–269. 17 indexed citations

19.

Ravic, M. & Paul Turner. (1990). Study of a potential effect of chlortenoxicam on the anticoagulant activity of warfarin. European Journal of Pharmacology. 183(3). 1030–1030.

20.

Warrington, Steve, et al.. (1990). Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation.. PubMed. 66 Suppl 4. S35–40. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact